Rationale for Therapeutic Silencing of Alpha-Synuclein in Parkinson’s Disease
Author:
Publisher
The Korean Movement Disorder Society
Subject
Clinical Neurology,Neurology
Link
http://www.e-jmd.org/upload/jmd-4-1-1-1.pdf
Reference59 articles.
1. The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years
2. Dementia and survival in Parkinson disease: A 12-year population study
3. Risk tables for parkinsonism and Parkinson's disease
4. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030
5. Medical Services Utilization and Prognosis in Parkinson Disease: A Population-Based Study
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Decreasing the intrinsically disordered protein α-synuclein levels by targeting its structured mRNA with a ribonuclease-targeting chimera;Proceedings of the National Academy of Sciences;2024-01-05
2. Treatment of Parkinson's Disease: Current Treatments and Recent Therapeutic Developments;Current Drug Discovery Technologies;2023-09
3. siRNA polymer conjugates for the delivery of RNAi therapeutics for the treatment of Parkinson’s disease;Nanomedical Drug Delivery for Neurodegenerative Diseases;2022
4. Parkinson's disease: Alterations in iron and redox biology as a key to unlock therapeutic strategies;Redox Biology;2021-05
5. OUP accepted manuscript;Brain;2021
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3